Recovery & Repair
BPC-157
aka Body Protection Compound 157 · PL 14736 · Bepecin · PLD-116 · bpc · bpc157 · wolverine peptide · body protection compound · wolverine stack · bpc 157 · bcp-157 · bcp157 · bc157 · bbc157 · b157 · boc157
Grade
A lab-made peptide based on a fragment of a protein found in stomach fluid, widely studied in animals for tissue repair but essentially untested in humans.
- Class
- Synthetic pentadecapeptide (15 amino acids)
- Evidence
- Grade D · Animal data only
- Sport / WADA
- Prohibited in sport. BPC-157 was added to the World Anti-Doping Agency Prohibited List in 2022 under S0 (non-approved substances), so it is banned for tested athletes at all times.
- Last reviewed
- 2026-06
Grade D · Animal data only
Why this grade
Extensive animal research but almost no completed human trials. The healing signals seen in rats have not been shown in people.
What is it?
Why people buy it
People buy it to heal injuries faster. Gym-goers use it for sore tendons, pulled muscles and joint pain. Some take it for stomach and gut problems.
What we actually know
- •In rats, it helped injuries heal faster, including tendons, muscles and the gut.
- •Almost all of this work comes from one research group.
- •There are no finished, published studies of injecting it in people.
- •It is not a licensed medicine in the UK, or anywhere else.
What might happen
- •It might help healing in people, or it might do nothing. Nobody has tested it properly.
- •Nobody knows the long-term risks, because there is no safety data in people.
- •It helps new blood vessels grow. Doctors worry this could be bad for anyone with cancer. This is a theory, not proven.
- •It is sold online as 'not for human use'. The bottle may not contain what the label says.
- •It is banned in sport. Tested athletes can fail a drugs test.
Bottom line
Promising in rats, unknown in people. You are the experiment.
Know someone taking this?
Send on WhatsAppThink of BPC-157 as a repair crew that has done striking work on scale models in a laboratory. Every before-and-after photo is of a miniature house. We have not yet watched the same crew work on a real, inhabited house.
How is it meant to work?
The leading explanation is that BPC-157 promotes angiogenesis, the formation of new blood vessels, by upregulating VEGFR2 signalling. Better blood supply to damaged tissue then supports repair. Animal work also points to modulation of the nitric-oxide system, increased expression of growth-hormone receptors in tendon cells, and effects on dopamine and serotonin pathways that may explain the reported gut-brain and neuroprotective findings.
What's it studied for?
Research contexts. Not proven uses, and not recommendations.
Does the human evidence stack up?
Very limited. The most-cited human work concerns the oral analogue PL 14736 in early inflammatory-bowel-disease studies. For the injectable form that people actually buy, there are no completed peer-reviewed human efficacy trials and no published human pharmacokinetics or safety data. Claims of benefit in people rest on extrapolation from animals and anecdote, not controlled human research.
What could go wrong?
- !Almost the entire evidence base is animal data from a single research lineage, with limited independent replication.
- !No published human safety data for injectable use, so long-term risks are genuinely unknown.
- !Grey-market product purity is unverified, and what is in the vial may not match the label.
- !There is a theoretical concern that strong pro-angiogenic effects could be unwanted in anyone with cancer or proliferative disease.
- !It is marketed heavily online with claims that far outrun the actual human evidence.
Is it legal in the UK?
BPC-157 is not a licensed medicine in the UK and has no marketing authorisation from the MHRA. It is not a controlled drug, but cannot legally be sold or supplied for human consumption. Online sellers avoid this by labelling it 'for research use only / not for human consumption'. Selling it as a treatment or making medicinal claims breaches the Human Medicines Regulations.
Key trials
- · Phase I/II (historical)· Not progressed to approval
PL 14736 (oral BPC-157 analogue) early-phase studies for inflammatory bowel disease
The closest thing to human data, and it is for the oral analogue, not the injectable form sold online.
Sources
- 01Brain–gut axis and pentadecapeptide BPC 157: theoretical and practical implications — Sikiric P et al., Current Neuropharmacology (2016)
Representative review from the originating research group summarising the breadth of preclinical claims.
- 02Stable Gastric Pentadecapeptide BPC 157 in the Treatment of Wound Healing and Tissue Repair (review) — Seiwerth S et al., Current Pharmaceutical Design (2018)
Overview of the angiogenesis / tendon-healing mechanism evidence in animals.
- 03Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review — Józwiak M et al., Pharmaceuticals (2025)
Recent independent review noting the gap between preclinical breadth and clinical evidence.
Related
Compare with
Before you trust a vial
Peptides are freeze-dried for a reason. If you have seen BPC-157 sold pre-mixed in a ready-to-use pen or syringe, here is why that is a red flag for potency, sterility and dosing.
Storage & stability →Stay posted
Follow BPC-157
We'll email you only when BPC-157's evidence actually changes — a new human trial, a grade change, a safety signal. No spam, nothing for sale.